ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) SUZHOU, China, Oct. 20, 2025 /PRNewswire/ — CStone Pharmaceuticals ("CStone," HKEX: 2616),… CISION PRNewswireOctober 20, 2025
Press Release Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group SYDNEY, Oct. 20, 2025 /PRNewswire/ — The Brattle Group has welcomed Dr. Luke… CISION PRNewswireOctober 20, 2025
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances SHANGHAI, Oct. 20, 2025 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global… CISION PRNewswireOctober 20, 2025
Webull Reduces Minimum ASX Trading Fee To $1 Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading… CISION PRNewswireOctober 20, 2025
Press Release Yaber Expands Its Global Footprint — Now Available at JB Hi-Fi Across Australia SYDNEY, Oct. 20, 2025 /PRNewswire/ — Yaber, a pioneer of entertainment projectors,… CISION PRNewswireOctober 20, 2025
Razor Labs Expands Predictive Maintenance Coverage in Australia with Mobile Fleet AI Solution Launch at IMARC 2025 The company introduces its proven Mobile Fleet Predictive Maintenance solution to Australia,… CISION PRNewswireOctober 20, 2025
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 HONG KONG, Oct. 19, 2025 /PRNewswire/ — On October 19, 2025, Akeso (9926.HK)… CISION PRNewswireOctober 19, 2025
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60,… CISION PRNewswireOctober 19, 2025